ANI 파마슈티컬스, Inc.
DE ˙ DB ˙ US00182C1036
€54.50 0.00 (0.00%)
2023-08-21
주가
SecurityDE:BSFA / ANI Pharmaceuticals, Inc.
InstitutionProShare Advisors LLC
Latest Disclosed Ownership3,936 shares
Latest Disclosed Value $ 302,678
ProShare Advisors LLC reports 12.92% decrease in ownership of BSFA / ANI Pharmaceuticals, Inc.

On April 24, 2026 - ProShare Advisors LLC filed a 13F-HR form disclosing ownership of 3,936 shares of ANI Pharmaceuticals, Inc. (DE:BSFA) valued at $302,678 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 4,520 shares of ANI Pharmaceuticals, Inc.. This represents a change in shares of -12.92% during the quarter. The current value of the position is $214,512 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F ANI PHARMACEUTICALS COM 00182C103 3,936 -584 -12.92 303 -15.17 0.0004
2026-02-06 2025-12-31 13F ANI PHARMACEUTICALS COM 00182C103 4,520 336 8.03 357 -7.05 0.0006
2025-11-06 2025-09-30 13F ANI PHARMACEUTICALS COM 00182C103 4,184 -662 -13.66 383 21.20 0.0008
2025-08-07 2025-06-30 13F ANI PHARMACEUTICALS COM 00182C103 4,846 -454 -8.57 316 -10.73 0.0006
2025-05-08 2025-03-31 13F ANI PHARMACEUTICALS COM 00182C103 5,300 -1,232 -18.86 355 -1.94 0.0008
2025-02-14 2024-12-31 13F ANI PHARMACEUTICALS COM 00182C103 6,532 1,469 29.01 361 19.54 0.0008
2024-11-14 2024-09-30 13F ANI PHARMACEUTICALS COM 00182C103 5,063 1,493 41.82 302 33.04 0.0007
2024-08-13 2024-06-30 13F ANI PHARMACEUTICALS COM 00182C103 3,570 -877 -19.72 227 -26.06 0.0006
2024-05-08 2024-03-31 13F ANI PHARMACEUTICALS COM 00182C103 4,447 404 9.99 307 38.29 0.0008
2024-02-14 2023-12-31 13F ANI PHARMACEUTICALS COM 00182C103 4,043 472 13.22 223 7.25 0.0007
2023-11-13 2023-09-30 13F ANI PHARMACEUTICALS COM 00182C103 3,571 3,571 207 0.0006
2020-05-15 2020-03-31 13F ANI PHARMACEUTICALS COM 00182C103 0 -4,106 -100.00 0 -100.00
2020-02-12 2019-12-31 13F ANI PHARMACEUTICALS COM 00182C103 4,106 -442 -9.72 253 -23.56 0.0012
2019-11-12 2019-09-30 13F ANI PHARMACEUTICALS COM 00182C103 4,548 -50 -1.09 331 -12.43 0.0019
2019-08-13 2019-06-30 13F ANI PHARMACEUTICALS COM 00182C103 4,598 -534 -10.41 378 4.42 0.0023
2019-05-15 2019-03-31 13F ANI PHARMACEUTICALS COM 00182C103 5,132 39 0.77 362 58.08 0.0022
2019-02-14 2018-12-31 13F ANI PHARMACEUTICALS COM 00182C103 5,093 -914 -15.22 229 -32.65 0.0016
2018-11-14 2018-09-30 13F ANI PHARMACEUTICALS COM 00182C103 6,007 -293 -4.65 340 -19.24 0.0023
2018-08-13 2018-06-30 13F ANI PHARMACEUTICALS COM 00182C103 6,300 -389 -5.82 421 8.23 0.0028
2018-05-14 2018-03-31 13F ANI PHARMACEUTICALS COM 00182C103 6,689 -1,044 -13.50 389 -21.89 0.0025
2018-02-14 2017-12-31 13F ANI PHARMACEUTICALS COM 00182C103 7,733 453 6.22 498 30.37 0.0035
2017-11-13 2017-09-30 13F ANI PHARMACEUTICALS COM 00182C103 7,280 479 7.04 382 20.13 0.0035
2017-08-11 2017-06-30 13F ANI PHARMACEUTICALS COM 00182C103 6,801 -477 -6.55 318 -11.67 0.0032
2017-05-12 2017-03-31 13F/A-2 ANI PHARMACEUTICALS COM 00182C103 7,278 -1,822 -20.02 360 -34.78 0.0038
2017-05-08 2017-03-31 13F/A-1 ANI PHARMACEUTICALS COM 00182C103 7,278 0 360 0.0038
2017-04-25 2017-03-31 13F ANI PHARMACEUTICALS COM 00182C103 7,278 360
2017-02-13 2016-12-31 13F ANI PHARMACEUTICALS COM 00182C103 9,100 897 10.94 552 1.47 0.0061
2016-11-10 2016-09-30 13F ANI PHARMACEUTICALS COM 00182C103 8,203 -1,489 -15.36 544 0.55 0.0076
2016-08-12 2016-06-30 13F ANI PHARMACEUTICALS COM 00182C103 9,692 81 0.84 541 66.98 0.0070
2016-05-06 2016-03-31 13F ANI PHARMACEUTICALS COM 00182C103 9,611 -962 -9.10 324 -32.08 0.0045
2016-02-05 2015-12-31 13F ANI PHARMACEUTICALS COM 00182C103 10,573 946 9.83 477 25.53 0.0058
2015-11-06 2015-09-30 13F ANI PHARMACEUTICALS COM 00182C103 9,627 -636 -6.20 380 -40.35 0.0053
2015-08-11 2015-06-30 13F ANI PHARMACEUTICALS COM 00182C103 10,263 -462 -4.31 637 -5.07 0.0088
2015-05-08 2015-03-31 13F ANI PHARMACEUTICALS COM 00182C103 10,725 10,725 671 0.0079
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.